Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis

By V. Thourani, S. Kodali, R. Makkar, Howard C Herrmann, Mathew R. Williams, V. Babaliaros, R. Smalling, Scott Lim, Chris S. Malaisrie, S. Kapadia and 18 more. The Lancet, 2016

948 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8cc04d1d616209ed9f1c7f9197d875e3021d0db5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “In an observational study of the SAPIEN 3 valve (63), TAVR was performed in 1,077 intermediate-risk patients with severe symptomatic AS, with the transfemoral approach used in 88% of patients.”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “In an observational study of the SAPIEN 3 valve (63), TAVR was performed in 1,077 intermediate-risk patients with severe symptomatic AS, with the transfemoral approach used in 88% of patients.”